479 related articles for article (PubMed ID: 8635500)
1. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
2. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
4. Calcium modulates the expression of urokinase plasminogen activator and plasminogen activator inhibitor 2 by human keratinocytes.
Lyons-Giordano B; Lazarus GS
Exp Dermatol; 1994 Apr; 3(2):85-8. PubMed ID: 7921656
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1 beta and tumor necrosis factor-alpha.
Bechtel MJ; Reinartz J; Rox JM; Inndorf S; Schaefer BM; Kramer MD
Exp Cell Res; 1996 Mar; 223(2):395-404. PubMed ID: 8601416
[TBL] [Abstract][Full Text] [Related]
6. Suppression of keratinocyte proliferation by plasminogen activator inhibitor-2.
Hibino T; Matsuda Y; Takahashi T; Goetinck PF
J Invest Dermatol; 1999 Jan; 112(1):85-90. PubMed ID: 9886269
[TBL] [Abstract][Full Text] [Related]
7. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
[TBL] [Abstract][Full Text] [Related]
8. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Buø L; Bjørnland K; Karlsrud TS; Kvale D; Kjønniksen I; Fodstad O; Brandtzaeg P; Johansen HT; Aasen AO
Anticancer Res; 1994; 14(6B):2445-51. PubMed ID: 7872665
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
Schaefer BM; Jaeger C; Drepper E; Kramer MD
Autoimmunity; 1996; 23(3):155-64. PubMed ID: 8879451
[TBL] [Abstract][Full Text] [Related]
10. Hydrocortisone regulates the dynamics of plasminogen activator and plasminogen activator inhibitor expression in cultured murine keratinocytes.
Bator JM; Cohen RL; Chambers DA
Exp Cell Res; 1998 Jul; 242(1):110-9. PubMed ID: 9665808
[TBL] [Abstract][Full Text] [Related]
11. Dispase-mediated basal detachment of cultured keratinocytes induces urokinase-type plasminogen activator (uPA) and its receptor (uPA-R, CD87).
Schaefer BM; Reinartz J; Bechtel MJ; Inndorf S; Lang E; Kramer MD
Exp Cell Res; 1996 Nov; 228(2):246-53. PubMed ID: 8912717
[TBL] [Abstract][Full Text] [Related]
12. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
Sipley JD; Alexander DS; Testa JE; Quigley JP
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor type 2 (PAI-2) is present in normal human conjunctiva.
Massaro-Giordano M; Marshall CM; Lavker RM; Jensen PJ; Risse Marsh BC
J Cell Physiol; 2005 Nov; 205(2):295-301. PubMed ID: 15887231
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor type-2 in the lesional epidermis of lupus erythematosus.
Bechtel MJ; Schaefer BM; Kramer MD
Br J Dermatol; 1996 Mar; 134(3):411-9. PubMed ID: 8731662
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator system in pemphigus vulgaris.
Schaefer BM; Jaeger CJ; Kramer MD
Br J Dermatol; 1996 Nov; 135(5):726-32. PubMed ID: 8977672
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
19. Topological localization of plasminogen activator inhibitor type 2.
Liew MA; McPhun V; Baker MS
Cytometry; 2000 May; 40(1):32-41. PubMed ID: 10754515
[TBL] [Abstract][Full Text] [Related]
20. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
